Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 1992 / Article

Sexually Transmitted Diseases | Open Access

Volume 3 |Article ID 743419 | https://doi.org/10.1155/1992/743419

Hazel Talbot, Barbara Romanowski, "In Vitro Activities of Sparfloxacin, Ceftriaxone, Penicillin, Tetracycline and Doxycycline against Chlamydia trachomatis and Neisseria gonhorrhoeae", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 3, Article ID 743419, 4 pages, 1992. https://doi.org/10.1155/1992/743419

In Vitro Activities of Sparfloxacin, Ceftriaxone, Penicillin, Tetracycline and Doxycycline against Chlamydia trachomatis and Neisseria gonhorrhoeae

Received12 Jan 1991
Accepted13 Apr 1991

Abstract

In vitro sparfloxacin was highly active against 223 penicillin-susceptible isolates of Neisseria gonorrhoeae with a 90% minimal inhibitory concentration (MIC90) of 0.004 μg/mL. Resistant strains of N gonorrhoeae totalled 55; 32 were penicillinase-producing and 23 chromosomally resistant. The MIC90 for these isolates was 0.004 μg/mL and 0.008 μg/mL, respectively. Chlamydia trachomatis was also very susceptible with an MIC50 of 0.063 μg/mL and a 50% minimal bactericidal concentration of 0.032 μg/mL for 11 isolates.

Copyright © 1992 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views61
Downloads164
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.